Preparing for 2025: Drug Trends to Watch
GLP-1s: The GLP-1 receptor agonist class keeps growing. These medications, which started as a game-changer for diabetes management, are now utilized for other comorbidities. Looking ahead, we expect to see more GLP-1s expanding their indications and generic versions hitting the market as patents expire. GLP-1 therapies work best when combined with a supportive healthcare team and strategies that encourage building healthier habits.
Biosimilars: Biosimilars are nearly identical to their biologic counterparts and bring much-needed competition, which can lower costs for patients and the system as a whole. We’re expecting more biosimilar launches in 2025, which should help make these treatments more accessible and affordable.
Prescription Drug Spending: Prescription drug spending is on track to account for $863 billion in health expenditure by 2028, according to a JAMA Network analysis. CMS also predicts we’ll see more high-cost specialty drugs hitting the market, while fewer generics are expected to launch. This combination could push drug spending even higher.
KEY TAKEAWAYS
As we start 2025, it’s clear that these trends are set to shape the healthcare landscape in a big way. Whether it’s the expanding role of GLP-1s, the rise of biosimilars, or the shifting drug spending picture, staying on top of these changes will be key. Working together and staying innovative will help us navigate these shifts and continue delivering great care while managing costs.
(The information provided is for educational purposes and should not be used during any medical emergency or for the diagnosis or treatment of any conditions. Consult with your health care provider for diagnosis and treatment of all medical conditions. Call 911 for all medical emergencies.)